MA39342B2 - Anticorps il -21 - Google Patents

Anticorps il -21

Info

Publication number
MA39342B2
MA39342B2 MA39342A MA39342A MA39342B2 MA 39342 B2 MA39342 B2 MA 39342B2 MA 39342 A MA39342 A MA 39342A MA 39342 A MA39342 A MA 39342A MA 39342 B2 MA39342 B2 MA 39342B2
Authority
MA
Morocco
Prior art keywords
antibodies
methods
compositions
antibody
antagonism
Prior art date
Application number
MA39342A
Other languages
English (en)
Other versions
MA39342A1 (fr
Inventor
Julian Davies
Fabio Magrini
Andrea Paula Martin
Neelufar Mozaffarian
Chetankumar Natvarlal Patel
Oliver Schroeder
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39342A1 publication Critical patent/MA39342A1/fr
Publication of MA39342B2 publication Critical patent/MA39342B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps humanisés construits qui ont une forte affinité de liaison pour il -21 humain et qui le neutralisent, des procédés d'utilisation desdits anticorps pour traiter des maladies dans lesquelles l'antagonisme ou la neutralisation des effets d'il -21 est garanti, telles que des maladies auto-immunes, des compositions et des procédés de production par recombinaison des anticorps, et des compositions pharmaceutiques comprenant lesdits anticorps.
MA39342A 2014-03-21 2015-03-13 Anticorps il -21 MA39342B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21
PCT/US2015/020383 WO2015142637A1 (fr) 2014-03-21 2015-03-13 Anticorps il -21

Publications (2)

Publication Number Publication Date
MA39342A1 MA39342A1 (fr) 2018-03-30
MA39342B2 true MA39342B2 (fr) 2020-03-31

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39342A MA39342B2 (fr) 2014-03-21 2015-03-13 Anticorps il -21

Country Status (24)

Country Link
US (1) US9394362B2 (fr)
EP (1) EP3119806B1 (fr)
JP (2) JP6053989B2 (fr)
KR (1) KR101859857B1 (fr)
CN (1) CN106061999B (fr)
AP (1) AP2016009450A0 (fr)
AR (1) AR099625A1 (fr)
AU (1) AU2015231777B2 (fr)
BR (1) BR112016019176A2 (fr)
CA (1) CA2939543C (fr)
CL (1) CL2016002281A1 (fr)
EA (1) EA033335B1 (fr)
EC (1) ECSP16075416A (fr)
ES (1) ES2774422T3 (fr)
IL (1) IL246909A0 (fr)
MA (1) MA39342B2 (fr)
MX (1) MX2016012120A (fr)
MY (1) MY177915A (fr)
NZ (1) NZ722518A (fr)
PE (1) PE20161221A1 (fr)
PH (1) PH12016501820A1 (fr)
SG (1) SG11201606705QA (fr)
TW (1) TWI646105B (fr)
WO (1) WO2015142637A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3128997T3 (pl) 2014-04-08 2020-12-28 Boston Pharmaceuticals Inc. Cząsteczki wiążące specyficznie il-21 i ich zastosowania
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
US11267882B2 (en) 2016-03-31 2022-03-08 Eli Lilly And Company Methods of detecting human IL-21
US11554131B2 (en) * 2018-05-31 2023-01-17 Glycom A/S Mixture of HMOs for treating autoimmune diseases
MX2021001281A (es) 2018-08-02 2021-07-15 Dyne Therapeutics Inc Complejos dirigidos a músculos y sus usos para el tratamiento de distrofinopatías.
CA3141626A1 (fr) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Nouveaux promedicaments d'il-15 et leurs procedes d'utilisation
JP2022545439A (ja) 2019-08-21 2022-10-27 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－２１プロドラッグおよびその使用方法
KR20240032945A (ko) * 2021-07-09 2024-03-12 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
IL309912A (en) * 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and their uses for the treatment of dystrophinopathy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512006A (en) * 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
ES2340280T3 (es) * 2003-03-14 2010-06-01 Wyeth Llc Anticuerpos dirigidos contra el receptor de il-21 humano y uso de los mismos.
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
ES2409835T3 (es) * 2005-11-28 2013-06-28 Zymogenetics, Inc. Antagonistas de IL-21
EP1960433A2 (fr) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Antagonistes du recepteur de il-21
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
CA2910933C (fr) * 2007-12-07 2017-04-11 Zymogenetics, Inc. Anticorps monoclonaux anti-il-21 humain
EP2796466B1 (fr) * 2007-12-07 2017-11-22 ZymoGenetics, Inc. Molécules d'anticorps humanisés spécifiques pour l'IL-31
US20130323259A1 (en) 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
CN103702721A (zh) * 2011-05-31 2014-04-02 诺沃—诺迪斯克有限公司 Il-21表位和il-21配体

Also Published As

Publication number Publication date
KR20160124166A (ko) 2016-10-26
US20150266954A1 (en) 2015-09-24
KR101859857B1 (ko) 2018-05-18
AP2016009450A0 (en) 2016-09-30
PE20161221A1 (es) 2016-11-12
JP2016520088A (ja) 2016-07-11
AU2015231777B2 (en) 2017-08-03
BR112016019176A2 (pt) 2017-10-10
US9394362B2 (en) 2016-07-19
MX2016012120A (es) 2016-12-09
JP6053989B2 (ja) 2017-01-11
JP2017093435A (ja) 2017-06-01
EA033335B1 (ru) 2019-09-30
MA39342A1 (fr) 2018-03-30
TW201623330A (zh) 2016-07-01
CA2939543A1 (fr) 2015-09-24
NZ722518A (en) 2017-12-22
IL246909A0 (en) 2016-09-29
CL2016002281A1 (es) 2017-06-23
CN106061999A (zh) 2016-10-26
CA2939543C (fr) 2018-01-16
ES2774422T3 (es) 2020-07-21
PH12016501820A1 (en) 2016-11-07
AU2015231777A1 (en) 2016-08-18
ECSP16075416A (es) 2018-05-31
WO2015142637A1 (fr) 2015-09-24
EP3119806A4 (fr) 2017-11-01
EA201691521A1 (ru) 2017-02-28
MY177915A (en) 2020-09-25
JP6373944B2 (ja) 2018-08-15
CN106061999B (zh) 2020-07-31
EP3119806A1 (fr) 2017-01-25
EP3119806B1 (fr) 2020-01-01
TWI646105B (zh) 2019-01-01
SG11201606705QA (en) 2016-09-29
AR099625A1 (es) 2016-08-03

Similar Documents

Publication Publication Date Title
MA39342B2 (fr) Anticorps il -21
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
WO2018017864A3 (fr) Agents de liaison à pvrig et leurs utilisations
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471A (fr) Compositions comprenant des souches bactériennes
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
EA201792047A1 (ru) Новые соединения
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA55434A (fr) Compositions comprenant des souches bactériennes
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
EP4339615A3 (fr) Anticorps anti-pd-1
WO2015132675A3 (fr) Procédés et compositions pour modifier une réponse immunitaire
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
WO2017049038A3 (fr) Anticorps anti-cd115
MX2021005085A (es) Formulacion de anticuerpo.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
WO2016020882A3 (fr) Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
EA202192488A1 (ru) Антитела против tsg-6 и их применения